An Observational Retrospective Study Investigating Changes in Seizure Adequacy Parameters of Electroconvulsive Therapy and Their Relationships to Clinical Outcome in Schizophrenia and Schizoaffective Disorder

2020 ◽  
pp. 155005942093207
Author(s):  
Onur Durmaz ◽  
Tuba Öcek Baş
Keyword(s):  
Heart Rate ◽  
Retrospective Study ◽  
Clinical Outcome ◽  
Electroconvulsive Therapy ◽  
Schizoaffective Disorder ◽  
Predictor Variable ◽  
Peak Heart Rate ◽  
Syndrome Scale ◽  
Scale Scores ◽  
Negative Syndrome

The aim of the current study was to investigate a possible relationship between electroconvulsive therapy (ECT) seizure adequacy parameters and clinical outcome as well as differences between ECT responders and nonresponders in terms of ECT seizure parameters in patients diagnosed with schizophrenia and schizoaffective disorder. First and last ECT records data, sociodemographic variables, and baseline and post ECT Positive and Negative Syndrome Scale scores were obtained. Maximum sustained power was higher in last ECT in favor of responders while peak heart rate was higher in ECT nonresponders than responders in first ECT. Stimulus doses were higher in last ECT than in the first ECT in both groups. No predictor variable was observed among baseline ECT seizure parameters for clinical improvement. Study was insufficient to yield a precise finding pointing a relationship between electrophysiological seizure parameters and clinical outcome in schizophrenia and schizoaffective disorder.

Clinical outcome after stop continuation and maintenance electroconvulsive therapy: A longitudinal retrospective study

2019 ◽  
Vol 29 ◽  
pp. S357-S358
Author(s):  
P. Serra ◽  
E. Martínez-Amorós ◽  
L. Urraca ◽  
X. Goldeberg ◽  
D.J. Palao ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Clinical Outcome ◽  
Electroconvulsive Therapy

CHANGES IN SERUM LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR WITH ELECTROCONVULSIVE THERAPY AND PHARMACOTHERAPY AND ITS CLINICAL CORRELATES IN MALE SCHIZOPHRENIA PATIENTS

2021 ◽  
pp. 1-21
Author(s):  
Ibrahim Akbas ◽  
Ozlem Devrim Balaban
Keyword(s):  
Blood Sample ◽  
Electroconvulsive Therapy ◽  
Serum Levels ◽  
Treatment Modalities ◽  
Healthy Population ◽  
Sample Collection ◽  
Level Increase ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Serum Bdnf

Abstract Objectives: It has been postulated that neurotrophin dysregulation leads to disorganization in neuronal networks, which results in schizophrenia. The current study sets out to evaluate if the finding of lower BDNF levels in schizophrenia patients could be confirmed in an independent cohort, and to investigate if the BDNF levels can be altered with different treatment modalities such as electroconvulsive therapy (ECT) and/or antipsychotic pharmacotherapy (PT). Methods: A total of 54 male patients with schizophrenia and 35 healthy controls were included in the study. Schizophrenia patients were subdivided into two groups as the ones who underwent ECT+PT and only PT. Clinical and sociodemographic data questionnaire, Positive and Negative Syndrome Scale (PANSS) and blood sample collection for BDNF assessment were applied to all patients (on first and last days of admissions) and healthy participants (on the day of the interview). Then, clinical parameters and blood sample outcomes were statistically analyzed. Results: Mean BDNF levels of healthy individuals was significantly higher than mean pre and post-treatment BDNF levels in both PT only and ECT+PT groups. While serum BDNF levels did not increase after ECT+PT, there was a trend level increase in the PT only group. There was no significant correlation between the change in serum BDNF levels with total PANSS scores in either group after treatment. Conclusions: We could confirm previously suggested data of lower serum BDNF levels in schizophrenia patients compared to healthy population but we couldn’t find significant increase in serum BDNF levels with ECT+PT or only PT as some previous studies suggested.

Negative symptoms in schizophrenia: correlation with clinical and genetic factors

2021 ◽  
Author(s):  
Aline Hajj ◽  
Souheil Hallit ◽  
Karam Chamoun ◽  
Hala Sacre ◽  
Sahar Obeid ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Genetic Factors ◽  
Multivariable Analysis ◽  
Clinical Factors ◽  
Clinical Genetic ◽  
Self Evaluation ◽  
Syndrome Scale ◽  
Daily Dose ◽  
Scale Scores ◽  
Negative Syndrome

Aim: Explore the possible association between clinical factors and genetic variants of the dopamine pathways and negative symptoms. Materials & methods: Negative symptoms were assessed in 206 patients with schizophrenia using the Arabic version of the self-evaluation of negative symptoms scale and the Positive and Negative Syndrome Scale. Genotyping for COMT, DRD2, MTHFR and OPRM1 genes was performed. Results: Multivariable analysis showed that higher self-evaluation of negative symptoms scale scores were significantly associated with higher age, higher chlorpromazine-equivalent daily dose for typical antipsychotics and in married patients. Higher negative Positive and Negative Syndrome Scale scores were significantly associated with women and having the CT genotype for MTHFR c.677C>T (β = 4.25; p = 0.008) compared with CC patients. Conclusion: Understanding both clinical/genetic factors could help improve the treatment of patients.

Modified Electroconvulsive Therapy in Pseudocholinesterase Deficiency: A Case Report

2017 ◽  
Vol 41 (S1) ◽  
pp. s770-s771
Author(s):  
E. Yildizhan ◽  
N.B. Tomruk ◽  
M. Dereli ◽  
A. Özdemir ◽  
H. Yıldırım ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Neurological Diseases ◽  
Respiratory Muscles ◽  
Response To Treatment ◽  
Anesthetic Agents ◽  
Syndrome Scale ◽  
History Of ◽  
Competing Interest ◽  
Modified Electroconvulsive Therapy ◽  
Negative Syndrome

Introduction.Pseudocholinesterase (PCHE) deficiency is an inherited condition, in which recovery from anesthetic agents like succinylcholine and mivacurium is slow and complicated with prolonged paralysis of respiratory muscles in susceptible patients. Succinylcholine is used very frequently as a muscle relaxant during the procedure.Objectives.In Bakirkoy research and training hospital for psychiatric and neurological diseases, 24.310 patients were hospitalized for acute conditions and 3490 of these patients were treated with electroconvulsive therapy (ECT) in 3 years. We present a very rare case that we encountered in our practice; a severe PCHE deficiency case that could have complicated the modified ECT procedure unless necessary precautions were taken.Aims.Detection of PCHE levels of all patients eligible for ECT is part of our pre-ECT assessments procedure, and the case presented here shows the benefits of this method.Methods.The patient is a 29-year-old woman, with a 15 year history of schizophrenia. She was hospitalized for homicidal risk and refusal of treatment. Inadequate clinical response with pharmacological interventions and continuous aggressive excitations directed us to consider ECT.Results.After the detection of PCHE deficiency (PCHE level: 126 U/L), we performed the modified ECT with propophol and rocuronium instead of succinylcholine as usual. Sugammadex 100 mg was used for fastening the recovery. Response to treatment, which is recorded with positive and negative syndrome scale, was good and we completed 9 ECT sessions without complication.Conclusions.Screening for PCHE levels in the pre-ECT assessments is efficacious in order to decrease the complications of the ECT procedure.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia

2018 ◽  
Vol 28 (1) ◽  
pp. 177-186 ◽  
Author(s):  
Edimansyah Abdin ◽  
Siow Ann Chong ◽  
Esmond Seow ◽  
Swapna Verma ◽  
Kelvin Bryan Tan ◽  
...  
Keyword(s):  
Syndrome Scale ◽  
Scale Scores ◽  
Negative Syndrome ◽  
Utility Scores

Electroconvulsive Therapy in a Psychiatric Intensive Care Unit

1994 ◽  
Vol 28 (2) ◽  
pp. 269-273 ◽  
Author(s):  
R. Julian Hafner ◽  
Gwili Holme
Keyword(s):  
Intensive Care Unit ◽  
Bipolar Disorder ◽  
Intensive Care ◽  
Clinical Outcome ◽  
Electroconvulsive Therapy ◽  
Schizoaffective Disorder ◽  
Psychotic Depression ◽  
Rapid Effect

This study reviewed all patients (N = 37) treated with ECT in a psychiatric intensive care unit during 1989–91. Diagnoses were: psychotic depression (8); bipolar disorder, manic phase (13); schizoaffective disorder (14); and schizophrenia (2). All patients were very severely disturbed and had failed to respond to medication given at highest levels judged to be safe, usually over 3–4 weeks. Response to ECT was generally rapid and marked, allowing substantial reductions in medication. To achieve the same clinical outcome for each course of ECT, 50% more unilateral than bilateral treatments were required, suggesting that bilateral ECT has a more rapid effect in this highly disturbed population.

scholarly journals Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder

2007 ◽  
Vol 191 (2) ◽  
pp. 131-139 ◽  
Author(s):  
Nicholas A. Keks ◽  
Michael Ingham ◽  
Akbar Khan ◽  
Keith Karcher
Keyword(s):  
Adverse Event ◽  
Schizoaffective Disorder ◽  
Factor Scores ◽  
Efficacy And Safety ◽  
Oral Olanzapine ◽  
Syndrome Scale ◽  
Dsm Iv ◽  
Long Acting ◽  
Negative Syndrome ◽  
To Receive

BackgroundThe efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic.AimsTo compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder.MethodPatients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day).ResultsIn the 13-week phase, long-acting risperidone was at least as effective as (not inferior to) oral olanzapine. In the 12-month phase, significant improvements in the Positive and Negative Syndrome Scale (PANSS) total and factor scores from baseline to month 12 and end-point were seen in both groups of patients. Few patients discontinued treatment because of an adverse event.ConclusionsBoth treatments were efficacious and well tolerated.

Long-acting risperidone in stable patients with schizoaffective disorder

2005 ◽  
Vol 19 (5_suppl) ◽  
pp. 22-31 ◽  
Author(s):  
A. Mohl ◽  
K. Westlye ◽  
S. Opjordsmoen ◽  
A. Lex ◽  
A. Schreiner ◽  
...  
Keyword(s):  
Schizoaffective Disorder ◽  
Psychiatric Symptoms ◽  
Drug Induced ◽  
Mood Symptom ◽  
Syndrome Scale ◽  
Sf 36 ◽  
Symptom Domains ◽  
Satisfaction With Treatment ◽  
Long Acting ◽  
Negative Syndrome

Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. The present analysis investigated the efficacy and tolerability of direct transition from other antipsychotics to risperidone long-acting injectable in patients with schizoaffective disorder. Patients aged ≥ 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25mg (increased to 37.5 or 50mg, if necessary) every 2 weeks for 6 months. The analysis included 249 patients (47% male; mean age 43 years), of whom 74% completed the 6-month study. Mean scores for the total Positive and Negative Syndrome Scale (PANSS) and all three subscales were significantly reduced from baseline to week 4 (p < 0.001), with further improvements until treatment endpoint. Significant improvements from baseline to endpoint were seen in the mood symptom domains of anxiety/depression (10.4±4.1 vs 8.7±3.9) and uncontrolled hostility/excitement (7.6±3.6 vs 6.9±3.8). Mean Global Assessment of Function (GAF) score improved significantly from 59.4±15.6 at baseline to 66.4±17.7 (p < 0.001) at endpoint. Of 87 patients hospitalized at baseline, 67% were discharged at endpoint. Both quality of life (SF-36) and satisfaction with treatment were improved significantly at endpoint. Total ESRS scores fell progressively throughout the study, and the reduction was already statistically significant (p < 0.001) at 4 weeks. Small but statistically significant (p < 0.001) mean shifts of 1.8% were seen in body weight and Body Mass Index (BMI). Patients with schizoaffective disorder derived several benefits from a change to risperidone long-acting injectable, including reductions in psychiatric symptoms (particularly the mood symptom domains) and a reduction in the severity of drug-induced neurological movement disorders.

scholarly journals L’impatto farmacoeconomico del trattamento della schizofrenia con antipsicotici tipici ed atipici: l’esperienza di un DSM della Regione Sicilia

2005 ◽  
Vol 6 (4) ◽  
pp. 365-375
Author(s):  
Tommaso Federico ◽  
Carmelo Astuto ◽  
Giuseppe Bongiorno ◽  
Domenico Majorana ◽  
Giovanni Biricolti ◽  
...  
Keyword(s):  
Antipsychotic Drugs ◽  
Clinical Performance ◽  
Psychiatric Services ◽  
Economic Data ◽  
Health Community ◽  
Syndrome Scale ◽  
Scale Scores ◽  
Potential Benefits ◽  
Acquisition Costs ◽  
Negative Syndrome

Il presente lavoro è stato realizzato con il patrocinio del Dipartimento Ispettorato Regionale Sanitario dell.Assessorato per la Sanità della Regione Sicilia, nella persona del Dirigente Generale Dott. Saverio Ciriminna BACKGROUND: The comparatively high acquisition costs of the new antipsychotic drugs have induced the mental health community to look closely at their potential benefits. OBJECTIVE: To compare the clinical and economic outcomes associated with olanzapine, risperidone and typical neuroleptics treatment for schizophrenia. METHODS:Amulticenter, observational, two-years long, retrospective and prospective study was conducted with 229 psychotic patients (in charge by psychiatric Centers of Regione Sicilia - Italy). Clinical outcomes were assessed using changes in CGI (Clinical Global Impression) and PANSS (Positive and Negative Syndrome Scale) scores. The economic data collection included pharmacological and non-pharmacological resources consumption (hospitalizations, medical/nurse visits, etc.). The economic evaluation was conducted in the perspective of the Local Psychiatric Services. RESULTS: The results in terms of clinical performance indicated an advantage (statistically significant) in the olanzapine group of patients. The pharmacological costs were significantly lower (p0,05). Treatment with olanzapine was associated with a lower non-pharmacological resources consumption and showed a general reduction (p

Sign in / Sign up

Export Citation Format

Share Document